LONDON, Sept. 20, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, announces the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria.
Drug firm Vivimed Labs NSE 3.16 % on Monday said it has received approval from the Uzbekistan government for two products.
Cadila Pharmaceuticals Limited has announced the launch of Bilastine syrup (30 ml) and Bilastine tablets in the strength of 20mg. Bilastine, an antihistamine drug, is used in allergic rhinitis treatment.